We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Funds to Boost British Efforts to Develop Chlamydia Vaccine

By LabMedica International staff writers
Posted on 16 Aug 2015
Print article
An infusion of new funding is expected to boost efforts by researchers in the United Kingdom to develop a vaccine to prevent Chlamydia infection.

Chlamydiae are small gram-negative obligate intracellular microorganisms that preferentially infect squamocolumnar epithelial cells. Chlamydia trachomatis infection, with nearly 200,000 new cases per year in the United Kingdom, is the most commonly reported bacterial sexually transmitted disease in the United States and a leading cause of infertility in women.

In a major effort to control the spread of chlamydial infection, the United Kingdom's Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; London, United Kingdom) has committed GBP 377,000 to aid in the development of a vaccine. The project will be conducted by Prokarium Ltd. (London, United Kingdom), a biotechnology company that develops transformational oral vaccines. Prokarium will add an additional 121,000 GBP to the research program.

The development effort will be shared by Prokarium and its collaborator, Dr. Robin Shattock, professor of mucosal infection and immunity at Imperial College London (United Kingdom). The plan is to complete the preclinical development of the Chlamydia vaccine in time for clinical trials in 2017.

Dr. Steve Chambers, CEO of SynbiCITE, said, "The new Prokarium vaccine was selected for funding because the need for a Chlamydia vaccine is significant and the potential for this approach both for Chlamydia and as a model for treating other infections in the medium-term is very encouraging.”

Dr. Steve Chatfield, chairman of Prokarium, said, “This SynbiCITE funding allows us to test a vaccine against the one of the world’s most serious sexually transmitted infections. Prokarium is now well set up to work with the best of the best in the vaccine arena.”

Related Links:

SynbiCITE
Prokarium Ltd.
Imperial College London


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.